Emily A Kendall1, Shelly Malhotra2, Sarah Cook-Scalise2, David W Dowdy3, Claudia M Denkinger4,5. 1. Division of Infectious Diseases and Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Global Alliance for Tuberculosis Drug Development, New York, New York, USA. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4. Division of Tropical Medicine, Center of Infectious Disease, Heidelberg University, Heidelberg, Germany. 5. Foundation for Innovative New Diagnostics, Geneva, Switzerland.
Abstract
BACKGROUND: To appropriately treat tuberculosis (TB) with regimens that combine novel and older drugs, evidence-based, context-specific strategies for drug-susceptibility testing (DST) will be required. METHODS: We created a Markov state-transition model of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)-containing regimen. We estimated clinical outcomes and resource utilization with no FQ-DST, universal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB ("targeted FQ-DST"). We considered scenarios of stronger (South Africa) and weaker (Southeast Asia) correlation of fluoroquinolone resistance with rifampin resistance, with sensitivity analysis for other setting and regimen characteristics. RESULTS: Relative to no FQ-DST, targeted FQ-DST increased cure of FQ-resistant TB by 7.5% (interquartile range [IQR], 6.7%-9.2%) in South Africa and 1.7% (IQR, 0.7%-2.5%) in Southeast Asia. However, rare FQ resistance among the more prevalent rifampin-susceptible TB accounted for 50% of FQ-resistant TB in South Africa and 83% in Southeast Asia. As a result, universal FQ-DST further increased cure of FQ-resistant TB by 3.4% (IQR, 2.3%-5.4%) in South Africa and 5.8% (IQR, 5.1%-6.3%) in Southeast Asia. With targeted FQ-DST, 1 additional patient was cured per 50 (IQR, 42-70) tests in South Africa and 44 (IQR, 37-51) in Southeast Asia. When expanding from targeted to universal FQ-DST, 1 additional cure required 3500 (IQR, 2300-5500) tests in South Africa and 410 (IQR, 370-450) in Southeast Asia. CONCLUSIONS: FQ-DST improved patient outcomes and was particularly important for high-risk patient groups and less robust regimens. A universal strategy was favored in generalized epidemics of fluoroquinolone resistance.
BACKGROUND: To appropriately treat tuberculosis (TB) with regimens that combine novel and older drugs, evidence-based, context-specific strategies for drug-susceptibility testing (DST) will be required. METHODS: We created a Markov state-transition model of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)-containing regimen. We estimated clinical outcomes and resource utilization with no FQ-DST, universal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB ("targeted FQ-DST"). We considered scenarios of stronger (South Africa) and weaker (Southeast Asia) correlation of fluoroquinolone resistance with rifampin resistance, with sensitivity analysis for other setting and regimen characteristics. RESULTS: Relative to no FQ-DST, targeted FQ-DST increased cure of FQ-resistant TB by 7.5% (interquartile range [IQR], 6.7%-9.2%) in South Africa and 1.7% (IQR, 0.7%-2.5%) in Southeast Asia. However, rare FQ resistance among the more prevalent rifampin-susceptible TB accounted for 50% of FQ-resistant TB in South Africa and 83% in Southeast Asia. As a result, universal FQ-DST further increased cure of FQ-resistant TB by 3.4% (IQR, 2.3%-5.4%) in South Africa and 5.8% (IQR, 5.1%-6.3%) in Southeast Asia. With targeted FQ-DST, 1 additional patient was cured per 50 (IQR, 42-70) tests in South Africa and 44 (IQR, 37-51) in Southeast Asia. When expanding from targeted to universal FQ-DST, 1 additional cure required 3500 (IQR, 2300-5500) tests in South Africa and 410 (IQR, 370-450) in Southeast Asia. CONCLUSIONS:FQ-DST improved patient outcomes and was particularly important for high-risk patient groups and less robust regimens. A universal strategy was favored in generalized epidemics of fluoroquinolone resistance.
Authors: Margaretha de Vos; Brigitta Derendinger; Tania Dolby; John Simpson; Paul D van Helden; John E Rice; Lawrence J Wangh; Grant Theron; Robin M Warren Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: Dodge R Lim; Anna S Dean; Mary Rosary Taguinod-Santiago; Angeli Borbe-Reyes; Andrea Maurizio Cabibbe; Matteo Zignol; Ramon P Basilio; Anna Marie Celina Garfin; Maria Cecilia G Ama Journal: Eur Respir J Date: 2018-03-22 Impact factor: 16.671
Authors: Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione Journal: Lancet Infect Dis Date: 2016-07-07 Impact factor: 25.071
Authors: Conor D Tweed; Rodney Dawson; Divan A Burger; Almari Conradie; Angela M Crook; Carl M Mendel; Francesca Conradie; Andreas H Diacon; Nyanda E Ntinginya; Daniel E Everitt; Frederick Haraka; Mengchun Li; Christo H van Niekerk; Alphonse Okwera; Mohammed S Rassool; Klaus Reither; Modulakgotla A Sebe; Suzanne Staples; Ebrahim Variava; Melvin Spigelman Journal: Lancet Respir Med Date: 2019-11-12 Impact factor: 30.700
Authors: Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; Claudia M Denkinger; David W Dowdy Journal: BMC Infect Dis Date: 2019-09-09 Impact factor: 3.090